2 recruiting. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow nivolumab plus relatlimab: new trials by email Literature Review of nivolumab plus relatlimab trials Research Report on nivolumab plus relatlimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma IMA203, nivolumab plus relatlimab, lifileucel - Melanoma, Cutaneous Malignant | Phase 3 | Recruiting | Immatics US, Inc. | 360 | 2025-01-14 | 2026-08-18 |
| Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin Nivolumab, Nivolumab plus Relatlimab - Squamous Cell Carcinoma of the Skin | Phase 2 | Recruiting | Salzburger Landeskliniken | 61 | 2017-03-06 | 2024-04-18 |
Melanoma, Cutaneous Malignant (1)
Immatics US, Inc. (1) · Salzburger Landeskliniken (1)
Austria (1) · Canada (1) · France (1) · Germany (1) · Netherlands (1) · United Kingdom (1) · United States (1)
Cedrik Britten, M.D. (1) · Martin Laimer, MD (1)